{"id":"NCT01241760","sponsor":"Janssen Infectious Diseases BVBA","briefTitle":"VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection","officialTitle":"A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-08","completion":"2012-11","firstPosted":"2010-11-16","resultsPosted":"2014-06-04","lastUpdate":"2014-06-04"},"enrollment":744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Genotype 1 Chronic Hepatitis C","Treatment Naive"],"interventions":[{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Telaprevir","otherNames":[]},{"type":"DRUG","name":"Pegylated interferon alfa-2a","otherNames":[]},{"type":"DRUG","name":"Telaprevir","otherNames":[]}],"arms":[{"label":"001 T(q8h) / PR","type":"EXPERIMENTAL"},{"label":"002 T(b.i.d.) / PR","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)","timeFrame":"End of trial, 12 weeks after last planned dose","effectByArm":[{"arm":"T12(q8h)/PR","deltaMin":72.8,"sd":null},{"arm":"T12(b.i.d.)/PR","deltaMin":74.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":99,"countries":["United States","Australia","Austria","Belgium","Brazil","France","Germany","Ireland","Mexico","Poland","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["25653396","24316262"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":371},"commonTop":["Fatigue","Pruritus","Anaemia","Nausea","Rash"]}}